ASIC3 and acute myeloid leukemia: In silico analyses indicated that certain subtypes of AML with abnormal karyotypes—inv (16) or t (15:17)—also had slightly reduced levels of ASIC3 from the curated database (Supplemental Figure 11H), and ASIC3 expression levels were positively correlated with the overall survival of patients with AML (Supplemental Figure 11I), which strongly suggests ASIC3, indeed, acts as a tumor suppressor in human AML.